Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 1 November 2023, 19:00 HKT/SGT

Source: DC Healthcare
DC Healthcare Unveils Innovative Skincare Range 'newB' Under Subsidiary Ten Doctors Sdn Bhd
Advanced Skincare Solutions Designed by Aesthetic Experts Set to Transform the Industry Landscape; Further Diversifying DC Healthcare's Portfolio

KUALA LUMPUR, Nov 1, 2023 - (ACN Newswire) - DC Healthcare Holdings Berhad ("DC Healthcare" or the "Company"), an aesthetic medical services provider specialising in the provision of non-invasive and minimally invasive procedures, announced today the launch of 'newB,' a state-of-the-art skincare line developed by its subsidiary, Ten Doctors Sdn Bhd (10DRS). The new range is segmented into two categories: newB Premium Ageless and newB Premium Hydration, both formulated to set new standards in skincare efficacy.

Dr. Chong Tze Sheng, Managing Director of DC Healthcare
Dr. Chong Tze Sheng, Managing Director of DC Healthcare

Engineered with the revolutionary ingredient DiamondC60™, the newB Premium Ageless range delivers potent anti-ageing benefits. This ground-breaking ingredient contains Japan Quality Fullerene “The First Natural Fullerene in Malaysia directly from Japan”, exhibits superior anti-oxidative performance compared to traditional anti-ageing components like Vitamin C.

In parallel, the newB Premium Hydration collection is empowered by the innovative 7HA Boost Complex. This advanced formulation incorporates seven distinct molecular sizes of hyaluronic acid and FUCOGEL®, ensuring ultimate water-boost for lasting healthy, soft and plump skin.

Dr. Chong Tze Sheng, Managing Director of DC Healthcare, stated, “The launch of newB is a strategic move in diversifying our healthcare portfolio. Our skincare products are developed with scientific precision, catering to the evolving skincare needs of our clientele. These new product lines not only contribute to our revenue streams but also enhance our reputation as a comprehensive healthcare provider. We are particularly encouraged by the commercial applications of DiamondC60™, an ingredient that we believe will set new industry standards.”

Amid projections for the Malaysian aesthetic medicine market to register a CAGR of 18.8% from 2021 to 2027, the introduction of newB resonates with DC Healthcare's commitment to innovation and excellence. The new skincare ranges are available for purchase through multiple online platforms, including Shopee, Lazada, TikTok shop, and Watsons Malaysia Online Store.

Moving forward, DC Healthcare will continue to focus on its core business, which includes aesthetic services and innovative healthcare solutions like newB. The Company plans to expand existing clinics, invest in cutting-edge technology, and fortify its team of medical professionals to capitalise on the growth opportunities presented by the aesthetic medicine market.

As at 31 October 2023, the share price of DC Healthcare stands at 0.52 sen per share, reflecting a market capitalisation of RM518.1 million.

For more information, please visit this LINK.

Topic: Press release summary
Source: DC Healthcare

Sectors: BioTech, Healthcare & Pharm
From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

DC Healthcare
June 13, 2024 15:00 HKT/SGT
DC Healthcare's Approve All Resolutions in AGM
Apr 18, 2024 19:33 HKT/SGT
DC Healthcare Rides the Wave of Success with New Openings at Publika and Bukit Indah
Mar 25, 2024 19:00 HKT/SGT
DC Healthcare Continues Growth Momentum with Second DC Body Outlet Opening in USJ Taipan
Feb 29, 2024 11:20 HKT/SGT
DC Healthcare Further Expands into Perai, Pulau Pinang with Two New Outlets, and Introduces DC Body
Feb 21, 2024 20:00 HKT/SGT
DC Healthcare Announces Expansion with New Branches in Johor Bahru and Ipoh
July 17, 2023 11:00 HKT/SGT
DC Healthcare Debuts on ACE Market with a Premium of RM0.15 over IPO Price
June 27, 2023 13:00 HKT/SGT
DC Healthcare to Raise RM49.81 Million from IPO
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: